Emergent Biosolutions Inc. (NYSE:EBS) Stock Has Consensus Target Price of $10.00

Posted by Geri Gentry on Nov 4th, 2026

Shares of Emergent Biosolutions Inc. (NYSE:EBS – Get Free Report) have been assigned a consensus rating of “Hold” from the six brokerages that are covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $10.00.

Several research firms recently weighed in on EBS. Zacks Research upgraded Emergent Biosolutions to a “hold” rating in a research report on Tuesday, August 11th. Weiss Ratings upgraded Emergent Biosolutions from a “sell (d-)” rating to a “sell (d)” rating in a report on Friday, August 21st. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Emergent Biosolutions in a research report on Wednesday, September 9th. Finally, JPMorgan Chase & Co. assumed coverage on shares of Emergent Biosolutions in a report on Friday, August 21st. They set an “underweight” rating on the stock.

Get Our Latest Stock Report on EBS

Emergent Biosolutions Price Performance

Shares of EBS opened at $6.24 on Friday. The company has a 50-day simple moving average of $6.52 and a two-hundred day simple moving average of $7.99. The company has a debt-to-equity ratio of 1.70, a quick ratio of 2.95 and a current ratio of 5.42. Emergent Biosolutions has a one year low of $4.36 and a one year high of $14.06.

Emergent Biosolutions (NYSE:EBS – Get Free Report) last posted its earnings results on Monday, November 2nd. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. Emergent Biosolutions had a negative return on equity of 0.40% and a negative net margin of 40.16%. The firm had revenue of $110.00 million for the quarter, compared to the consensus estimate of $123.22 million. Research analysts anticipate that Emergent Biosolutions will post 0.13 earnings per share for the current fiscal year.

Insider Transactions at Emergent Biosolutions

In related news, Director Donald Degolyer sold 17,800 shares of the business’s stock in a transaction dated Wednesday, October 7th. The shares were sold at an average price of $7.09, for a total transaction of $126,202.00. Following the sale, the director owned 111,921 shares of the company’s stock, valued at $793,519.89. The trade was a 13.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Emergent Biosolutions

Institutional investors and hedge funds have recently made changes to their positions in the business. Integrated Wealth Concepts LLC purchased a new position in Emergent Biosolutions during the second quarter valued at $29,000. Public Employees Retirement System of Ohio bought a new stake in Emergent Biosolutions in the second quarter worth $36,000. Legal & General Group Plc bought a new stake in Emergent Biosolutions in the second quarter worth $44,000. Tocqueville Asset Management L.P. purchased a new stake in shares of Emergent Biosolutions in the second quarter worth $93,000. Finally, Vise Technologies Inc. purchased a new stake in shares of Emergent Biosolutions in the third quarter worth $96,000. Institutional investors own 78.40% of the company’s stock.

Key Stories Impacting Emergent Biosolutions

Here are the key news stories impacting Emergent Biosolutions this week:

Positive Sentiment: Third-quarter adjusted loss per share was $0.36, narrower than the $0.39 loss analysts expected. The company also said quarterly revenue of $110 million was in line with its own guidance. Earnings report
Positive Sentiment: Restructuring actions are expected to produce $40 million in annualized savings, which could support profitability as the company continues its transformation. Long-term investor takeaways
Neutral Sentiment: Trading in EBS was temporarily halted for an LULD pause. The notice gives no specific catalyst or directional signal, but indicates a period of elevated price volatility.
Negative Sentiment: Emergent cut its FY 2026 revenue outlook to $600 million–$645 million, below the $656.2 million consensus estimate. Coverage characterized this as a second consecutive cut to revenue and EBITDA guidance, raising concerns about the company’s near-term growth and execution. Guidance coverage
Negative Sentiment: Despite the adjusted EPS beat, quarterly revenue of $110 million fell short of analysts’ $123.22 million estimate, tempering the earnings surprise. Third-quarter results

Emergent Biosolutions Company Profile

(Get Free Report)

Emergent BioSolutions Inc is a life sciences company that develops, manufactures and supplies medical countermeasures for public health threats. Its portfolio has included products for protection against anthrax and smallpox, as well as treatments and emergency medicines used in overdose response and other acute-care settings.

The company has also provided contract development and manufacturing services for pharmaceutical and biotechnology companies, supporting activities such as drug substance and product manufacturing, packaging and related commercialization services.